awmsg logo



ceftaroline fosamil (Zinforo®)


Reference No. 3164

Publication date:
30/09/2016


Appraisal information

ceftaroline fosamil (Zinforo®) 600 mg powder for concentrate for solution for infusion


Company: AstraZeneca UK Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/09/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ceftaroline fosamil (Zinforo®) cannot be endorsed for use within NHS Wales for the treatment of complicated skin and soft tissue infections and community-acquired pneumonia in children from the age of 2 months to 18 years old.
Statement of Advice (SOA)
Download